Clinical Trial Update: AR-inhibitor Bicalutamide in Treating Patients With TNBC [Phase 2]

View source ↗

Summary

Phase 2 trial investigating the AR inhibitor bicalutamide for triple-negative breast cancer; current status is UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• bicalutamide (bicalutamide)

Snippet

Sponsor: Jinling Hospital, China | Conditions: Breast Neoplasms | Phase 2 | Status: UNKNOWN